PYRAMID-ANALYTICS
16.6.2022 09:02:14 CEST | Business Wire | Press release
BIG DATA ANALYTICS CONFERENCE – Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, announced today that Tom Warren has been appointed Regional Managing Director, UK and Ireland (UKI). Warren brings with him twelve years of experience leading high achieving teams, alongside his previous experience as a professional rugby player, to build upon Pyramid’s growth in the UKI. The company’s customers in the UKI include Ann Summers, Liberty London, and Premier Foods.
The appointment follows Pyramid Analytics’ recent oversubscribed US $120MM Series E funding round, which was announced at a special event on May 9 from Tower Bridge in London. Pyramid is doubling down on its investment in the UKI, a leading market for decision intelligence adoption. In 2022, the UK tech ecosystem hit a landmark valuation of $1 trillion . At the centre of this tech success story is London. Pyramid plans to double its headcount in London over the coming months, to then use London as a base to support its European expansion. The appointment of Warren highlights Pyramid’s commitment to, and ambitions for, the UK and Ireland.
Key Points:
- Pyramid Analytics, a decision intelligence platform provider, hires experienced technology sector leader Tom Warren to accelerate UKI growth. Warren has twelve years leading successful teams and customer relationship management.
- Pyramid expanding investment in UKI talent, sales and marketing, and partner expansion.
- Warren’s appointment is the first in a series of planned business development initiatives to support customer success and strategic accounts in this region.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
Warren’s remit is to build out the UK and Ireland business, which will involve enterprise sales, business development, and channel and solutions engineering functions. Having started his career as a professional rugby player, Tom Warren is excited about the challenge ahead.
Meet our new Managing Director
Warren had a successful career as a professional rugby player for Worcester Warriors , London Irish , Grand Parma in Italy and finally at Esher RFC . This included a Division 1 title for Worcester in 2004 and playing in an English Premiership semi-final and European Challenge Cup final for London Irish in 2006. After his retirement, Warren initially turned his hand to coaching as the Scrum Coach and Director of the Academy at Esher.
Since then, he has had a successful career in sales. His most recent role was as Area VP Northern Europe at the cloud-based logistics platform Bringg where he was responsible for building out the EMEA sales team. In a previous role as Senior Director for EMEA Enterprise renewals at Blue Prism, he successfully increased customer renewals from 82% to 88%, which accounted for a 113% increase in the 2019 financial year. He was also Regional Sales Director at ServiceNow, where he set up the first UK Commercial sales team and consistently exceeded targets for delivering new business to help grow the UK business.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics: “Tom has brought a vast wealth of expertise and insight to the Managing Director role. He has a strong history of leading impressively successful sales and customer relationship teams and has helped multiple companies expand their sales outreach into the EMEA region.
“As a former professional rugby player and with over twelve years of heading sales teams, we knew that Tom would bring strong leadership skills, courage and energy to our growing team here at Pyramid. We believe that Tom is the right individual to lead our already high performing team to continue our growth in the UK and Ireland, following our phenomenal Series E funding round performance.”
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics : “Pyramid is what’s next in analytics and the UK is what’s next for Pyramid. I am really excited to be joining Pyramid Analytics and even more so to be joining a successful and high performing team, which has been behind their expansion in the UK and Ireland.
“Our Series E funding round earlier this month was a real statement of intent from the company, showcasing our ambition to expand our UK and Ireland operations so that Decision Intelligence can continue to transform the way businesses operate in the region. I look forward to contributing to this great company and working towards our European expansion.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners , Jerusalem Venture Partners (JVP), Sequoia Capital , and Viola Growth . Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom